SPECIAL EDUCATIONAL PROGRAM

WEDNESDAY, OCTOBER 22, 2025 - 12:00 PM - 1:00 PM - LUNCH SYMPSOIUM BY INTEGRA

Date: 22 October 2025 Time: 11:45 am –1:00 pm

Innovations and Outcomes in Laparoscopic and Minimally Invasive Robotic Liver Resection with CUSA Technology

Presented by

Integra Lifesciences

This lunch symposium will explore the latest innovations and outcomes in laparoscopic and minimally invasive liver resection. Leading experts will share strategies for bleeding control, compare laparoscopic and open outcomes, and highlight the integration of advanced technologies such as CUSA Clarity and robotics. An interactive panel discussion will provide practical insights into adoption, safety, and team organization to support optimal surgical practice.

Agenda:
Bleeding Control & Central Hepatectomy: New Standards - Dr. Fernando Rotellar (Clínica Universidad de Navarra)

  • Essential bleeding control strategies
  • Hilar caudal approach and standardization pearls

Laparoscopic vs. Open Resection in Liver Cancer - Dr. Gonzalo Sapisochin MD, PhD, MSc (Vall d’Hebron, Barcelona)

  • Key outcome data and survival findings

Transforming Liver Surgery with CUSA and Robotics - Dr. Jason Hawksworth (Columbia University Irving Medical Center)

  • Integrating CUSA Clarity with robotic platforms: clinical impact and workflow
  • Practical insights and case highlights

Expert Panel & Audience Discussion - All Faculty

  • Adoption of new technology (CUSA, robotics)
  • Surgical strategies, anesthetic safety, and team organization
  • Audience Q&A

Speakers:

Dr. Fernando Rotellar, MD, PhD Professor of Surgery and Director, General and Digestive Surgery Department Clínica Universidad de Navarra, Pamplona, Spain

Dr. Gonzalo Sapisochin MD, PhD, MSc Chief of Department Department of General and Abdominal Surgery | Liver Transplantation Hospital Universitario Vall d'Hebron, Barcelona

Dr. Jason Hawksworth, MD Surgical Director, Adult Liver Transplantation, Chief of Hepatobiliary Surgery, Division of Abdominal Organ Transplant and Hepatobiliary Surgery, Director of Robotic Liver Surgery Program, Division of Abdominal Organ Transplant and Hepatobiliary Surgery at New York Presbyterian Hospital/Columbia University Irving Medical Center Associate Professor at Columbia University College of Physicians and Surgeons

Date: 23 October 2025 Time: 7:00–8:00 am

The evolving landscape of early-stage hepatobiliary cancers: best practices, clinical considerations and future directions

Presented by

AstraZeneca

This non-promotional scientific exchange symposium is organised and funded by AstraZeneca for healthcare professionals only.

During this symposium, data may refer to medicines or indications under investigation or that may not be approved in your country. The information should under no circumstances be regarded as a recommendation for use of the medicine or indication. Please consult your local prescribing information. AstraZeneca does not, under any circumstances, promote its products for off-label or unapproved uses

Meeting objectives:

  • Examine the current treatment landscape of earlier-stage hepatobiliary cancers and evaluate barriers to optimising outcomes
  • Exchange perspectives on the rationale for immunotherapy-based approaches in earlier stages of hepatobiliary cancers
  • Explore potential emerging treatment approaches and future considerations in patient management, with a focus on timely diagnosis and the role of the surgeon

Agenda

  • Welcome and introductions - Gonzalo Sapisochin
  • Current management and emerging therapeutic approaches for earlier stages of HCC - Gonzalo Sapisochin
    • Review of clinical management of resectable HCC and evidence gaps in this setting
    • Rationale and key data for immunotherapy-based regimens in earlier stages of HCC, including neoadjuvant, perioperative and downstaging approaches
  • Case study discussion: Clinical considerations for the evolving management of resectable HCC - Parissa Tabrizian and all faculty participation
    • Perspectives on potential integration of immunotherapy-based regimens into clinical care of patients with early HCC
    • Discuss considerations for defining recurrence risk in this setting
    • Key considerations for patient selection and MDT-driven decision-making in the context of emerging therapies
  • Unmet needs, evidence gaps and perspectives on emerging therapies for early-stage BTC - Albert Chan
    • Overview of current management approaches and remaining unmet needs for resectable BTC
    • Insights on emerging systemic therapies and evaluation of available evidence for immunotherapy-based regimens in early-stage BTC
  • Panel discussion: Key considerations for potential future management strategies in resectable BTC - Albert Chan and all faculty participation
    • Discussion of potential implications of novel treatment approaches on the clinical management of resectable BTC
    • Perspectives on the evolving role of surgeons in patient management and within the MDT
    • Exploring current limitations and future directions for the timely diagnosis of early-stage BTC, including key considerations for optimising patient care pathways
  • Audience Q&A

Speakers:

Dr Gonzalo Sapisochin (Chair, Canada/Spain)

Dr Parissa Tabrizian (Speaker, USA)

Prof Albert Chan (Speaker, Hong Kong)

Date: 23 October 2025 Time: 12:15–1:15 pm

Best in Bridging: TheraSphere Y-90 for Transplant Candidates

Presented by

Boston Scientific

Y-90 radioembolization has emerged as the #1 bridging therapy for liver transplant candidates in the US. Join us for an interactive lunch session as our experts share their experience with TheraSphere Y-90 - demonstrating superior tumor control, reduced waitlist dropout, and improved transplant outcomes.